Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 152 full-time employees. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The firm's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
06996.HK stock price ended at $3.38 on 木曜日, after dropping 3.15%
On the latest trading day Feb 12, 2026, the stock price of 06996.HK fell by 3.15%, dropping from $3.42 to $3.38. During the session, the stock saw a volatility of 3.89%, with prices oscillating between a daily low of $3.34 and a high of $3.47. On the latest trading day, the trading volume for 06996.HK rose by 508.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 2.0M shares were traded, with a market value of approximately $2.0B.